medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2022,
Номер
unknown
Опубликована: Апрель 29, 2022
Abstract
Importance
Omicron
is
phylogenetically-
and
antigenically-distinct
from
earlier
SARS-CoV-2
variants
the
original
vaccine
strain.
Protection
conferred
by
prior
infection
against
re-infection,
added
value
of
vaccination,
require
quantification.
Objective
To
estimate
protection
re-infection
hospitalization
heterologous
(non-Omicron)
and/or
up
to
three
doses
(ancestral,
Wuhan-like)
mRNA
vaccine.
Design
Test-negative
study
between
December
26
(epi-week
52),
2021
March
12
10),
2022.
Setting
Population-based,
province
Quebec,
Canada
Participants
Community-dwelling
≥12-year-olds
tested
for
SARS-CoV-2.
Exposures
Prior
laboratory-confirmed
with/without
vaccination.
Outcomes
Laboratory-confirmed
hospitalization,
presumed
genomic
surveillance.
The
odds
non-Omicron
vaccination
were
compared
among
cases/hospitalizations
versus
test-negative
controls
(single
randomly-selected
per
individual).
Adjusted
ratios
controlled
age,
sex,
testing-indication
epi-week.
Analyses
stratified
severity
time
since
last
or
dose.
Results
Without
reduced
risk
44%
(95%CI:38-48),
decreasing
66%
(95%CI:57-73)
at
3-5
months
35%
(95%CI:21-47)
9-11
post-infection
<30%
thereafter.
more
severe
infection,
greater
reduction:
8%
(95%CI:17-28),
43%
(95%CI:37-49)
68%
(95%CI:51-80)
asymptomatic,
symptomatic
ambulatory
hospitalized
infections.
effectiveness
was
consistently
significantly
higher
previously-infected
vs.
non-infected
individuals
65%
(95%CI:63-67)
20%
(95%CI:16-24)
one-dose;
(95%CI:67-70)
42%
(95%CI:41-44)
two
doses;
83%
(95%CI:81-84)
73%
(95%CI:72-73)
doses.
Infection-induced
81%
(95%CI:
66-89)
increasing
86%
(95%CI:77-99)
with
one,
94%
(95%CI:91-96)
97%(95%CI:94-99)
Two-dose
did
not
wane
across
11
differ
three-dose
despite
longer
follow-up
(median
158
27
days,
respectively).
Conclusions
relevance
provided
substantial
sustained
greatest
those
also
vaccinated.
In
context
program
goals
prevent
outcomes
preserve
healthcare
system
capacity,
>2
ancestral
Wuhan-like
may
be
marginal
incremental
individuals.
Emerging Microbes & Infections,
Год журнала:
2023,
Номер
12(1)
Опубликована: Янв. 3, 2023
The
rapid
evolution
of
SARS-CoV-2
Omicron
sublineages
mandates
a
better
understanding
viral
replication
and
cross-neutralization
among
these
sublineages.
Here
we
used
K18-hACE2
mice
primary
human
airway
cultures
to
examine
the
fitness
antigenic
relationship
In
both
cultures,
exhibited
order
BA.5
≥
BA.2
BA.2.12.1
>
BA.1;
no
difference
in
body
weight
loss
was
observed
different
sublineage-infected
mice.
BA.1-,
BA.2-,
BA.2.12.1-,
BA.5-infected
developed
distinguishable
cross-neutralizations
against
sublineages,
but
little
neutralization
index
virus
(i.e.
USA-WA1/2020)
or
Delta
variant.
Surprisingly,
higher
activity
heterologous
than
that
homologous
BA.5;
serum
neutralizing
titres
did
not
always
correlate
with
levels
infected
animals.
Our
results
revealed
distinct
cartography
support
bivalent
vaccine
approach.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(13), С. 7315 - 7315
Опубликована: Июнь 30, 2022
The
epidemic
curve
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
silently
rising
again.
Worldwide,
the
dominant
SARS-CoV-2
variant
concern
(VOC)
Omicron,
and
its
virological
characteristics,
such
as
transmissibility,
pathogenicity,
resistance
to
both
vaccine-
infection-induced
immunity
well
antiviral
drugs,
are
an
urgent
public
health
concern.
Omicron
has
five
major
sub-lineages;
February
2022,
BA.2
lineage
been
detected
in
several
European
Asian
countries,
becoming
predominant
real
antagonist
ongoing
surge.
Hence,
although
global
attention
currently
focused
on
dramatic,
historically
significant
events
multi-country
monkeypox
outbreak,
this
new
unlikely
fade
away
silence.
Many
aspects
still
unclear
controversial,
but
apparent
replication
advantage
higher
ability
escape
neutralizing
antibodies
induced
by
vaccination
previous
infection,
concerns.
Herein,
we
review
latest
publications
most
recent
available
literature
variant.
Communications Medicine,
Год журнала:
2023,
Номер
3(1)
Опубликована: Июнь 30, 2023
Routine
case
surveillance
data
for
SARS-CoV-2
are
incomplete,
unrepresentative,
missing
key
variables
of
interest,
and
may
be
increasingly
unreliable
timely
surge
detection
understanding
the
true
burden
infection.
Journal of the American Medical Directors Association,
Год журнала:
2023,
Номер
24(5), С. 753 - 758
Опубликована: Март 28, 2023
To
identify
factors
that
contribute
to
protection
from
infection
with
the
Omicron
variant
of
SARS-CoV-2
in
older
adults
nursing
and
retirement
homes.Longitudinal
cohort
study
retrospective
analysis
risk.997
residents
homes
Ontario,
Canada,
COVID
LTC
study.Residents
3
messenger
RNA
(mRNA)
dose
vaccinations
were
included
study.
was
determined
by
positive
nasopharyngeal
polymerase
chain
reaction
test
and/or
circulating
antinucleocapsid
IgG
antibodies.
Cumulative
probability
after
recent
COVID-19
assessed
log-rank
Kaplan-Meier
curves.
Cox
regression
used
assess
risk
age,
sex,
mRNA
vaccine
combination,
whether
individuals
received
a
fourth
dose,
as
well
COVID-19.In
total,
171
(17.2%)
had
presumed
between
December
15,
2021
(local
start
first
wave)
May
3,
2022.
Risk
not
different
age
[hazard
ratio
(95%
confidence
interval)
1.01
(0.99‒1.02)],
or
women
compared
men
[0.97
(0.70‒1.34)],
but
decreased
47%
doses
mRNA-1273
(Moderna)
BNT162b2
(Pfizer)
[0.53
(0.31-0.90)],
81%
any
[0.19
(0.12‒0.30)],
48%
months
prior
beginning
wave
[0.52,
(0.27‒0.99)].Vaccine
type
(ie,
mRNA-1273/Spikevax
vs
BNT162b2/Cominarty),
hybrid
immunity
COVID-19,
protective
against
variant.
These
data
emphasize
importance
type,
number
doses,
maintenance
reduction
breakthrough
infection.
findings
promote
continued
public
health
efforts
support
vaccination
programs
monitor
immunogenicity
adults.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2022,
Номер
unknown
Опубликована: Апрель 29, 2022
Abstract
Importance
Omicron
is
phylogenetically-
and
antigenically-distinct
from
earlier
SARS-CoV-2
variants
the
original
vaccine
strain.
Protection
conferred
by
prior
infection
against
re-infection,
added
value
of
vaccination,
require
quantification.
Objective
To
estimate
protection
re-infection
hospitalization
heterologous
(non-Omicron)
and/or
up
to
three
doses
(ancestral,
Wuhan-like)
mRNA
vaccine.
Design
Test-negative
study
between
December
26
(epi-week
52),
2021
March
12
10),
2022.
Setting
Population-based,
province
Quebec,
Canada
Participants
Community-dwelling
≥12-year-olds
tested
for
SARS-CoV-2.
Exposures
Prior
laboratory-confirmed
with/without
vaccination.
Outcomes
Laboratory-confirmed
hospitalization,
presumed
genomic
surveillance.
The
odds
non-Omicron
vaccination
were
compared
among
cases/hospitalizations
versus
test-negative
controls
(single
randomly-selected
per
individual).
Adjusted
ratios
controlled
age,
sex,
testing-indication
epi-week.
Analyses
stratified
severity
time
since
last
or
dose.
Results
Without
reduced
risk
44%
(95%CI:38-48),
decreasing
66%
(95%CI:57-73)
at
3-5
months
35%
(95%CI:21-47)
9-11
post-infection
<30%
thereafter.
more
severe
infection,
greater
reduction:
8%
(95%CI:17-28),
43%
(95%CI:37-49)
68%
(95%CI:51-80)
asymptomatic,
symptomatic
ambulatory
hospitalized
infections.
effectiveness
was
consistently
significantly
higher
previously-infected
vs.
non-infected
individuals
65%
(95%CI:63-67)
20%
(95%CI:16-24)
one-dose;
(95%CI:67-70)
42%
(95%CI:41-44)
two
doses;
83%
(95%CI:81-84)
73%
(95%CI:72-73)
doses.
Infection-induced
81%
(95%CI:
66-89)
increasing
86%
(95%CI:77-99)
with
one,
94%
(95%CI:91-96)
97%(95%CI:94-99)
Two-dose
did
not
wane
across
11
differ
three-dose
despite
longer
follow-up
(median
158
27
days,
respectively).
Conclusions
relevance
provided
substantial
sustained
greatest
those
also
vaccinated.
In
context
program
goals
prevent
outcomes
preserve
healthcare
system
capacity,
>2
ancestral
Wuhan-like
may
be
marginal
incremental
individuals.
